EP2970910A4 - Immunothérapie ablative - Google Patents

Immunothérapie ablative

Info

Publication number: EP2970910A4
Authority: EP; European Patent Office
Prior art keywords: ablative; immunotherapy; ablative immunotherapy
Prior art date: 2013-03-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP14779681.7A

Other languages

German (de)

English (en)

Other versions

EP2970910A1 (fr

Inventor

Michael Har-Noy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunovative Therapies Ltd

Original Assignee

Immunovative Therapies Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-12

Filing date

2014-03-10

Publication date

2016-11-16

2013-03-12 Priority claimed from US13/796,171 external-priority patent/US9320794B2/en

2014-03-10 Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd

2016-01-20 Publication of EP2970910A1 publication Critical patent/EP2970910A1/fr

2016-11-16 Publication of EP2970910A4 publication Critical patent/EP2970910A4/fr

Status Ceased legal-status Critical Current

Links

238000009169 immunotherapy Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Hematology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Developmental Biology & Embryology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP14779681.7A 2013-03-12 2014-03-10 Immunothérapie ablative Ceased EP2970910A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13/796,171 US9320794B2 (en)	2006-11-13	2013-03-12	Ablative immunotherapy
PCT/US2014/022287 WO2014164396A1 (fr)	2013-03-12	2014-03-10	Immunothérapie ablative

Publications (2)

Publication Number	Publication Date
EP2970910A1 EP2970910A1 (fr)	2016-01-20
EP2970910A4 true EP2970910A4 (fr)	2016-11-16

Family

ID=51658863

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14779681.7A Ceased EP2970910A4 (fr)	2013-03-12	2014-03-10	Immunothérapie ablative

Country Status (11)

Country	Link
EP (1)	EP2970910A4 (fr)
JP (1)	JP6538647B2 (fr)
KR (1)	KR102265276B1 (fr)
CN (2)	CN105102613A (fr)
AU (2)	AU2014249374A1 (fr)
BR (1)	BR112015022974A8 (fr)
CA (1)	CA2904853A1 (fr)
IL (1)	IL241326B (fr)
PH (1)	PH12015502086A1 (fr)
SG (2)	SG11201507350WA (fr)
WO (1)	WO2014164396A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110151309B (zh) *	2018-02-14	2022-02-15	上海美杰医疗科技有限公司	多模态消融治疗术前规划方法及其设备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277368B1 (en) *	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1806849A (zh) *	2005-01-19	2006-07-26	上海三维生物技术有限公司	肿瘤的治疗方法
US7972594B2 (en) *	2006-11-13	2011-07-05	Immunovative Therapies Ltd.	Ablative immunotherapy
US20080112963A1 (en) *	2006-11-13	2008-05-15	Immunovative Therapies, Ltd.	Ablative immunotherapy
WO2009095033A1 (fr) *	2008-01-31	2009-08-06	Agirx Limited	Compositions de vaccin

2014
- 2014-03-10 SG SG11201507350WA patent/SG11201507350WA/en unknown
- 2014-03-10 AU AU2014249374A patent/AU2014249374A1/en not_active Abandoned
- 2014-03-10 KR KR1020157028277A patent/KR102265276B1/ko active Active
- 2014-03-10 WO PCT/US2014/022287 patent/WO2014164396A1/fr not_active Ceased
- 2014-03-10 SG SG10201707446PA patent/SG10201707446PA/en unknown
- 2014-03-10 JP JP2016500938A patent/JP6538647B2/ja active Active
- 2014-03-10 CA CA2904853A patent/CA2904853A1/fr not_active Abandoned
- 2014-03-10 BR BR112015022974A patent/BR112015022974A8/pt not_active Application Discontinuation
- 2014-03-10 CN CN201480014494.7A patent/CN105102613A/zh active Pending
- 2014-03-10 EP EP14779681.7A patent/EP2970910A4/fr not_active Ceased
- 2014-03-10 CN CN201710016168.5A patent/CN106581673A/zh active Pending
2015
- 2015-09-08 IL IL241326A patent/IL241326B/en active IP Right Grant
- 2015-09-11 PH PH12015502086A patent/PH12015502086A1/en unknown
2020
- 2020-02-21 AU AU2020201309A patent/AU2020201309A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277368B1 (en) *	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERHARD A. MÜLLER ET AL: "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", NATURE MEDICINE., vol. 6, no. 3, 1 March 2000 (2000-03-01), US, pages 332 - 336, XP055308901, ISSN: 1078-8956, DOI: 10.1038/73193 *
See also references of WO2014164396A1 *

Also Published As

Publication number	Publication date
IL241326B (en)	2021-05-31
CN105102613A (zh)	2015-11-25
IL241326A0 (en)	2015-11-30
WO2014164396A1 (fr)	2014-10-09
CN106581673A (zh)	2017-04-26
SG10201707446PA (en)	2017-10-30
EP2970910A1 (fr)	2016-01-20
AU2014249374A1 (en)	2015-09-24
SG11201507350WA (en)	2015-10-29
JP6538647B2 (ja)	2019-07-03
KR20150138234A (ko)	2015-12-09
BR112015022974A8 (pt)	2019-11-26
AU2020201309A1 (en)	2020-03-12
KR102265276B1 (ko)	2021-06-16
JP2016518319A (ja)	2016-06-23
PH12015502086A1 (en)	2016-01-18
BR112015022974A2 (pt)	2017-07-18
CA2904853A1 (fr)	2014-10-09

Legal Events

Date	Code	Title	Description
2015-12-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-01-20	17P	Request for examination filed	Effective date: 20150903
2016-01-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-01-20	AX	Request for extension of the european patent	Extension state: BA ME
2016-11-16	A4	Supplementary search report drawn up and despatched	Effective date: 20161019
2016-11-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 35/26 20060101ALI20161013BHEP Ipc: C12N 5/0783 20100101AFI20161013BHEP Ipc: A61P 31/00 20060101ALI20161013BHEP Ipc: A61P 35/00 20060101ALI20161013BHEP
2018-01-10	17Q	First examination report despatched	Effective date: 20171212
2020-07-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2020-10-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2020-12-02	18R	Application refused	Effective date: 20200724

Publication	Publication Date	Title
DK3342773T3 (da)	2021-02-15	Syk-hæmmere
DK3613453T3 (da)	2021-10-11	Fordamper
HRP20181334T1 (hr)	2018-11-16	Samohodno plovilo
DK2992104T3 (da)	2019-07-15	Fremgangsmåde til ekspression
DK3077047T3 (da)	2019-07-15	Aramcholsalte
DK3052081T3 (da)	2021-01-18	Pastil
DK3060460T3 (da)	2021-04-19	Saddel
DK3027598T3 (da)	2017-05-22	Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da)	2021-03-22	Bindestrimler
EP2943489A4 (fr)	2016-06-08	Momélotinib deutéré
DK2946640T3 (da)	2017-11-20	Langmuir-probe
DE102013106534B8 (de)	2015-06-18	Chromatographiepipettenspitze
EP2991647A4 (fr)	2016-10-12	Amléxanox deutéré
EP2970310A4 (fr)	2016-09-07	5-bromo-indirubines
EP2853297A4 (fr)	2016-02-24	Kendama
DK3071227T3 (da)	2021-01-18	Fiskevaccine
DE112014001252A5 (de)	2016-01-21	Aufbissschiene
DK3086679T3 (da)	2020-10-26	Sportssko
DK2981168T3 (da)	2020-04-06	Laminitiskile
EP2970910A4 (fr)	2016-11-16	Immunothérapie ablative
FI10138U1 (fi)	2013-06-28	Kelkkateltta
ES1078715Y (es)	2013-12-02	Mosquitera
DE112014005422A5 (de)	2016-09-01	Friktionsfalschdrallaggregat
BR112016000501A2 (pt)	2017-07-25	Nalador
FI10396U1 (fi)	2014-02-28	Tielana